Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia

NCT06933472 is registered in ClinicalTrials.gov with Alebund Pharmaceuticals as lead sponsor.

NCT NCT06933472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06933472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia
Lead sponsor
Alebund Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
June 13, 2025
Completion date
January 10, 2027
Enrollment
264 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, receiving dialysis, dialysis, esrd (end-stage renal disease), hyperphosphatemia